Determination of liver specific toxicities in rat hepatocytes by high content imaging during 2-week multiple treatment  by Germano, Davide et al.
Toxicology in Vitro 30 (2015) 79–94Contents lists available at ScienceDirect
Toxicology in Vitro
journal homepage: www.elsevier .com/locate / toxinvi tDetermination of liver speciﬁc toxicities in rat hepatocytes by high
content imaging during 2-week multiple treatmenthttp://dx.doi.org/10.1016/j.tiv.2014.05.009
0887-2333/ 2014 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Abbreviations: DILI, drug-induced liver injury; Mrp2, multidrug resistant protein
2; HCI, high content imaging.
⇑ Corresponding author. Address: Discovery and Investigative Safety, Preclinical
Safety, WKL-135.2.86, Novartis Institutes for Biomedical Research, Klybeckstrasse
141, CH-4057 Basel, Switzerland. Tel.: +41 61 324 1735; fax: +41 61 324 1893.
E-mail address: armin.wolf@novartis.com (A. Wolf).Davide Germano, Marianne Uteng, Francois Pognan, Salah-Dine Chibout, Armin Wolf ⇑
Discovery and Investigative Safety, Preclinical Safety, Novartis Institutes for Biomedical Research, CH-4057 Basel, Switzerland
a r t i c l e i n f oArticle history:
Received 27 January 2014
Accepted 19 May 2014
Available online 14 June 2014
Keywords:
High content imaging
Rat hepatocytes
Hepatotoxicity
In vitro model
Long-term culture
Safety proﬁlinga b s t r a c t
DILI is a major safety issue during drug development and one of the leading causes for market
withdrawal. Despite many efforts made in the past, the prediction of DILI using in vitro models remains
very unreliable. In the present study, the well-established hepatocyte Collagen I-Matrigel™ sandwich
culture was used, mimicking chronic drug treatment after multiple incubations for 14 days. Ten drugs
associated with different types of speciﬁc preclinical and clinical liver injury were evaluated at non-
cytotoxic concentrations. Mrp2-mediated transport, intracellular accumulation of neutral lipids and
phospholipids were selected as functional endpoints by using Cellomics™ Arrayscan technology and
assessed at ﬁve timepoints (day 1, 3, 7, 10, 14). Liver speciﬁc functional impairments after drug treatment
were enhanced over time and could be monitored by HCI already after few days and before cytotoxicity.
Phospholipidosis-inducing drugs Chlorpromazine and Amiodarone displayed the same response as
in vivo. Cyclosporin A, Chlorpromazine, and Troglitazone inhibited Mrp2-mediated biliary transport,
correlating with in vivo ﬁndings. Steatosis remained difﬁcult to be reproduced under the current
in vitro testing conditions, resulting into false negative and positive responses. The present results
suggest that the repeated long-term treatment of rat hepatocytes in the Collagen I-Matrigel™ sandwich
conﬁguration might be a suitable tool for safety proﬁling of the potential to induce phospholipidosis and
impair Mrp2-mediated transport processes, but not to predict steatosis.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Drug-induced liver injury (DILI) is one of the most common
adverse event leading to drug attrition during pharmaceutical
development (Kola and Landis, 2004) and to drug withdrawals
(Wilke et al., 2007) after market introduction. There are many
clinical situations and mechanisms leading to DILI. Intracellular
accumulation of lipids (steatosis) or phospholipids (phospholipido-
sis) and inhibition of biliary clearance (cholestasis and hyperbiliru-
binemia) are regarded as severe pathological features affecting the
liver.
Following impairment of multiple mechanisms such as mito-
chondrial b-oxidation, de novo fatty acid synthesis (lipogenesis)
or fatty acid release from adipose tissues (lipolysis), neutral lipidscan accumulate in hepatocytes leading to micro- and macro-
vesicular steatosis (Begriche et al., 2011; Labbe et al., 2008).
Long-term treatment of steatotic drugs may also lead to cirrhosis
and ﬁnally to liver failure (Begriche et al., 2011).
Multidrug resistance-associated protein 2 (Mrp2) is an ATP-
binding cassette (ABCC2) transporter located at the bile canalicular
membrane. It is a major efﬂux transporter involved in biliary
excretion, playing a crucial role in the biliary excretion of a wide
variety of organic anions, including glutathione, glutathione conju-
gates, sulfated and glucuronidated bile acids (Borst et al., 2006). In
addition, Mrp2 plays an important role for the biliary excretion of
bilirubin: the absence of Mrp2, such as in patients affected by
Dubin–Johnson Syndrome (DJS) or in transport deﬁcient (TR) rats,
has been associated with deregulation of bilirubin homeostasis
resulting into hyperbilirubinemia (Kartenbeck et al., 1996;
Paulusma et al., 1996). Inhibition of Mrp2-mediated biliary
clearance may result in lipid homeostasis impairment and toxic
accumulation of metabolites in the hepatocytes (Tang, 2007).
Phospholipidosis (PLD) is a lysosomal storage disorder charac-
terized by excessive accumulation of phospholipids in several
tissues, such as liver, kidney and lung. Cationic amphiphilic drugs
80 D. Germano et al. / Toxicology in Vitro 30 (2015) 79–94(CADs) have been demonstrated to possess a high potential to
induce PLD (Halliwell, 1997). The impaired degradation of
phospholipids by lysosomal phospholipases following CADs
administration seems to be the main mechanism (Reasor and
Kacew, 2001). Despite the evidence that drug-induced PLD is often
reversible and that toxicological implications remain uncertain, it
is still considered an adverse side effect by regulatory authorities
(Berridge et al., 2007) and some challenge for pharmaceutical
companies to circumvent. Therefore, the use of characterized pre-
dictive models is highly recommended in order to identify toxicity
potential in preclinical phases.
Primary hepatocytes are regarded as the gold standard for
assessing drug transport and metabolism in vitro. However, follow-
ing isolation and culture, primary hepatocytes may fail to maintain
their typical oriented apical and basolateral morphology as well as
hepatic functions. Without embedding in an extracellular matrix,
the expression and activity of cytochrome P450 (CYP) enzymes in
hepatocytes cultured on plastic remains stable only during a short
period. Loss of polarity can be avoided by culturing primary hepa-
tocytes in sandwich conﬁguration allowing longer periods of cul-
ture (Dunn et al., 1991), maintenance of liver functions (LeCluyse
et al., 1994; Tuschl et al., 2009) and characteristic gene expression
(Kim et al., 2010). Despite these evidences, many studies are per-
formed between 24 and 48 h, therefore exposing the cells to a
range of acute high doses not comparable to physiological concen-
trations. Here, a long-term culture and treatment of primary rat
hepatocytes in sandwich conﬁguration (Collagen I-Matrigel™)
was used; cells could be kept in culture for 15 days and were
shown to maintain typical liver functions. Regular additions of
Matrigel™ layers have been found to improve signiﬁcantly the
quality and functions of the hepatocytes. In order to mimic a
chronic treatment and to investigate the effect of 10 drugs with
known adverse side effects in rats and human, cells were exposed
daily to subtoxic concentrations for two weeks. The drugs were
selected by the Predict-IV (FP7) consortium, a collaborative large-
scale project, whose aim is to support the development of better
drug testing strategies, which can be used for safety proﬁling of
the most frequently affected target organs of toxicity (liver, kidney
and CNS) (Wolf et al., 2013). Multi-parametric morphological and
functional cellular responses, such as intracellular accumulation
of neutral lipids and lysosomal phospholipids together with inhibi-
tion of Mrp2-mediated canalicular transport, were analyzed with
the use of HCI technology, which has been shown to be a valuable
tool for investigating speciﬁc drug-induced hepatotoxic events
(Donato et al., 2012; McDonough et al., 2009; Tolosa et al., 2012;
van de Water et al., 2011; Xu et al., 2008).2. Materials and methods
2.1. Isolation and puriﬁcation of primary rat hepatocytes
Five to six weeks old male Wistar rats were purchased from CBP
Harlan. The animals had free access to food and water. Hepatocytes
were isolated according to a two-step collagenase perfusionmethod
(Paine et al., 1979; Seglen, 1976) with modiﬁcations (Paine, 1990).
Brieﬂy, rats were anaesthetized with an intraperitoneal injection
of sodium pentobarbitone (75 lg/g body weight). Liver perfusion
was performed through the portal vein with Ca2+/Mg2+-free pre-
perfusion buffer (0.5 mM EGTA (Fluka) supplemented with 10 mM
HEPES-bufferedHanks’ balanced salt solution (Invitrogen)) at a con-
stant ﬂow rate of 25 ml/min. After 7–8 min the pre-perfusion solu-
tion was replaced by the perfusion buffer (DMEM/F12 (Gibco)
supplemented with 0.3 M CaCl2 (Sigma), 1 M HEPES (Gibco), 1%
Pen/Strep/Glut (Invitrogen) containing, and 100 U/ml collagenase
A (Roche)) at decreasing ﬂow rates from 25 to 12 ml/min. Afteradditional 8–10 min perfusion, the liver was dissected and manu-
ally dissociated in 25 ml collagenase buffer. The resulting cell
suspensionwas ﬁltered through a 100 lmgauze into a 50 ml plastic
tube and then ﬁlled with cold wash buffer (DMEM/F12 supple-
mented with 20% FCS (HyClone), 1 M HEPES, 1% Pen/Strep/Glut).
Parenchymal cellswere separated from the previous cell suspension
by two cycles of low-speed centrifugation (50 g, 5 min, 4 C). The
supernatant was discarded and the cells were then re-suspended
in 25 ml of attachment medium (Williams’ Medium E supple-
mented with 10% FCS, 10 mM HEPES, 0.17 lM insulin (Sigma),
0.3 lM dexamethasone (Sigma), 1% Pen/Strep/Glut) and added to
a Percoll gradient (Percoll™ Plus (GEHealthcare), HBSS 10X (Gibco),
1 M HCl). After 10 min spinning (50 g, 4 C) the cells were re-sus-
pended and washed in attachment medium before viability deter-
mination by Trypan Blue. Hepatocytes preparations with viability
greater than 85% were used for cultivation.
2.2. Cell culture and long-term treatments
Hepatocytes were seeded (3.5  105 cells/well) on 24-well
collagen I-coated plates (BD Biocoat). After 2–3 h, non-attached
cells were removed and a top layer of Matrigel™ (250 lg/ml; BD
#356237) diluted in serum-free medium (DMEM/F12 supple-
mented with sodium pyruvate (Gibco), 1X Insulin/Transferrin/Sele-
nium (Gibco), 0.03 lM dexamethasone, 1% Pen/Strep, albumin
solution from bovine serum (Sigma)) was applied with pre-cooled
pipette. Medium was changed every 24 h. Hepatocyte morphology
was monitored daily. Other layers of Matrigel™ were added at
day 4 and 8 and 12 of culture. For selected experiments rat hepato-
cytes were cultured in presence of DMEM/F12 supplemented with
Recombinant Human Epidermal Growth Factor (hEGF, Invitrogen)
or 0.5% FCS and with HCM™ Bullet Kit (Hepatocyte Culture Med-
ium, Lonza). The following compounds chosen from a training set
used in the 7th EU Framework project Predict-IV were used for
the long-term term treatment: Cyclosporin A, Metformin
(Calbiochem, Switzerland); Rosiglitazone, Troglitazone (Cayman
Chemicals, USA); Amiodarone, Chlorpromazine hydrochloride,
Fenoﬁbrate, Ibuprofen, Acetaminophen, Valproic Acid sodium salt
(Sigma–Aldrich, Germany). Non-cytotoxic concentrations were
chosen (Table 2) and rat hepatocytes were exposed 14 days to per-
form chronic treatment. The treatments started 24 h after cell seed-
ing. All compounds were dissolved in DMSO and added to the
mediumwith a ﬁnal concentration of 0.1% vol/vol DMSO. Cells incu-
bated in the presence of 0.1% vol/vol DMSO were used as control.
2.3. Biochemical assays
ATP assay: ATP was measured with CellTiter-Glo Luminescent
Cell Viability Assay (Promega, USA) according to manufacturer’s
instructions.
Lactate Dehydrogenase (LDH) release: LDH release was measured
with Cytotoxicity Detection KitPlus (Roche, Germany) according to
manufacturer’s instructions.
Urea synthesis: Urea synthesis was measured with Biochain’s
Urea Assay Kit (Biochain, USA) according to manufacturer’s
instructions.
Albumin secretion: Albumin content was assessed with Rat Albu-
min ELISA Quantitation Set (Bethyl Laboratories (Montgomery, TX,
USA) according to the manufacturer’s instructions.
2.4. Microscopy imaging and analysis and functional assays
All ﬂuorescence microscopy images of were taken with Thermo
Scientiﬁc Cellomics™ Arrayscan VTI, with XF93 Hoechst, FITC,
TRITC excitation/emission ﬁlters and 10/20 objective. An
amount of at least 2000 cells per well were imaged (8–10
Table 1
Primers used in Real-Time Polymerase Chain Reaction.
Gene symbol Gene name Alias RefSeq Amplicon length
Abcb11 ATP-binding cassette, sub-family B (MDR/TAP), member 11 Bsep NM_031760.1 75
Abcb1b ATP-binding cassette, sub-family B (MDR/TAP), member 1B Mdr1 NM_012623.2 66
Abcc1 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 Mrp1 NM_022281.2 87
Abcc2 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 Cmoat NM_012833.1 78
Mrp2
Abcc3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 Mrp3 NM_080581.1 63
Abcc4 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 Mrp4 NM_133411.1 70
Slco1a1 Solute carrier organic anion transporter family, member 1a1 Oatp1 NM_017111.1 80
Oatp1a1
Slco1a4 Solute carrier organic anion transporter family, member 1a4 Oatp2 NM_131906.1 134
Oatp1a4
Slco1b2 Solute carrier organic anion transporter family, member 1b2 Oatp4 NM_031650.1 83
Oatp1b2
Cyp3a2 Cytochrome P450, family 3, subfamily a, polypeptide 2 Cyp3a11 NM_153312.2 116
Cyp7a1 Cytochrome P450, family 7, subfamily a, polypeptide 1 CHAP NM_012942.1 81
CYP7
CYP7S1
Nr1h4 Nuclear receptor subfamily 1, group H, member 4 Fxr NM_021745.1 95
Nr1i3 Nuclear receptor subfamily 1, group I, member 3 CAR NM_022941.3 63
Nr1i2 Nuclear receptor subfamily 1, group I, member 2 PXR NM_052980.2 59
Gapdh Glyceraldehyde-3-phosphate dehydrogenase Gapd NM_017008.3 87
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objective). Fluorescence intensities were quantiﬁed by using Spot
Detector and Compartmental Analysis BioApplication calculating
the sum of average ﬂuorescence intensity within a ring surround-
ing nuclei with a radius of 15 lm for each cell, followed by division
of total number of cells measured.
Mrp2-mediated transport measurement: Cells were washed twice
and incubated with pre-warmed HBSS (+Ca2+/Mg2+) 10 min at
37 C. Next, cells were stained with Hoechst 33,342 (10 lg/ml)
and 5-(and-6)-carboxy-20,70-dichloroﬂuorescein diacetate
(carboxy-DCFDA) (4 lM in DMSO) (Invitrogen, USA) to assess
Mrp2-mediated biliary transport and incubated 15 min at 37 C.
The images acquired with Cellomics™ Arrayscan were analyzed
by Spot Detector V4 BioApplication.
Neutral lipid accumulation: Cells were washed twice with HBSS
(+Ca2+/Mg2+), stained with Hoechst 33,342 and BODIPY 493/503
(4,4-diﬂuoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene)
(2 lM in DMSO) (Invitrogen, USA) and incubated 15 min at 37 C.
The images acquired with Cellomics™ Arrayscan were analyzed
by Compartmental Analysis V4 BioApplication.
Phospholipids accumulation: Cells were washed twice with HBSS
(+Ca2+/Mg2+) and stained HCS LipidTox™ Red (1:1000 in culture
medium) (Invitrogen, USA) for 24 h at 37 C in culture medium.
After 24 h, the cells were washed 3 times with HBSS (+Ca2+/
Mg2+), stained with Hoechst 33,342 and incubated 10 min at
37 C. The images acquired with Cellomics™ Arrayscan were ana-
lyzed by Spot Detector V4 BioApplication.
2.5. Real time–PCR (RT–PCR)
FastLane Cell Multiplex Kit (200), (Qiagen, USA) was used to iso-
late ﬁrst-strand cDNA directly from cultured cells without RNA
puriﬁcation according to manufacturer’s instructions. RT–PCR
was performed using a StepOnePlus™ Instrument (Applied Biosys-
tems, USA) in the presence of TaqMan Gene E probes (Table 1)
(Applied Biosystems, USA). Glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) was used as internal control. A volume of 20 ll
was the used for each reaction. Relative gene expression was
analyzed using the 2DDCt method.
2.6. Statistics
Statistical comparisons were performed between each dose
group and the control using two-way ANOVA. Values were ﬁrstnormalized within each experiment in percent of control, to make
the experiments comparable. The data were obtained from 3
independent experiments, each of them consisting of 3 replicates.
Statistical analysis was conducted using Graph Pad Prism 6
software. Differences compared to respective daily controls were
considered as statistically signiﬁcant for p < 0.05.3. Results
3.1. Improved cellular morphology and functionality by addition of
multiple Matrigel™ layers
Following isolation, primary rat hepatocytes were puriﬁed and
cultured in Collagen I-coated plates. After the addition of a layer
of Matrigel™, hepatocytes showed typical cuboidal morphology
within the same day (Fig. 1A), whereas the canalicular networks
were visible only after 2–3 days in culture (Fig. 1B). After 8 days
in culture rat hepatocytes started to lose their cuboidal morphol-
ogy and acquired spindle-like shape (Fig. 1C and D) together with
dead cell detachment from the wells (Fig. 1E). In contrast, cells
receiving a second layer of Matrigel™ on day 7 showed signiﬁcant
improvement of the culture quality. The cells maintained their
morphology together with a lower disruption of the canalicular
networks after 8 days (Fig. 1H–J).
In order to investigate whether the addition of further layers of
Matrigel™ would further improve the quality and the functional
properties of the hepatocytes, 3 (day 0, 5 and 10) or 4 layers (day
0, 4, 8 and 12) were added over a period of 14 days. No signiﬁcant
differences in terms of intracellular ATP and LDH release were
observed between day 1 and day 14 (Fig. 2A and B). The function-
ality of hepatocytes was investigated at day 14 of culture by incu-
bation of carboxy-DCFDA, a dye cleaved by cytosolic esterases
resulting in the formation of dichloroﬂuorescein (DCF), which is
then transported speciﬁcally by the canalicular transporter Mrp2
(Zamek-Gliszczynski et al., 2003). The number of cells, regarded
as valid objects, as well as the spot average area and intensity of
the ﬂuorescent signal within the object, were chosen as parameters
and illustrated in Fig. 2C–E. As shown in Fig. 2F–H, DCF accumu-
lated in the canaliculi, conﬁrming that hepatocytes cultured in
our conditions maintained their functional Mrp2 transporter activ-
ity. The intensity of ﬂuorescent signal was lower in the canaliculi of
adjacent hepatocytes cultured with 2 layers only (Fig. 2F), com-
pared to cells receiving 4 layers of Matrigel™ (Fig. 2H). Analysis
Table 2
Summary of in vitro results compared with preclinical/clinical Cmax and observed side effects. 0.1% DMSO was used as vehicle control.
Effects observed in liver
In vitro In vivo
Compounds and
Concentrations (lM)
Endpoints Lowest effective
concentration (lM)
Preclinical Clinical
Day
3
Day
7
Day
10
Day
14
Cmax (lM) Side effects Cmax (lM) Side effects
Cyclosporin A (CsA)
(0.3, 1, 3)
Mrp2
inhibition ;
3 1 1 1 (0.96–2.3) (Guan et al., 2011;
Ishizaki et al., 2008)
Cholestasis (Stone et al., 1987), Hyperbilirubinemia
(Roman et al., 1990)
(0.44–1.39)# Cholestasis (Myara et al., 1996), Hyperbilirubinemia
(Ertorer et al., 1997)
Neutral Lipids
"
3 1 0.3 0.3
Phospholipids
"
ATP ; 3 1
LDH " 3 1
Amiodarone (AMD)
(1, 2.5, 5)
Mrp2
inhibition ;
(0.6–2.14) (Fruncillo et al., 1985;
Rodrigues et al., 2012)
Phospholipidosis (Halliwell, 1997) (2.32–3.72)# Phospholipidosis (Poucell et al., 1984)
Neutral Lipids
"
Phospholipids
"
5 5 5 2.5
ATP ;
LDH " 5 5
Rosiglitazone (RGZ)
(10, 20, 50)
Mrp2
inhibition ;
(1.33–33.52) (Lakshmi and
Rajesh, 2011; Varanasi et al.,
2008)
Mitochondrial impairment (Feinstein et al., 2005) (1.35–2)# Hepatocellular damage (Floyd et al., 2009)
Neutral Lipids
"
50
Phospholipids
"
ATP ;
LDH " 50
Chlorpromazine
(CPZ) (1, 5, 10)
Mrp2
inhibition ;
1 5 1 5 (0.03–0.2) (Imamura et al., 1988;
Zhang et al., 2007)
Cholestasis (Barth et al., 1978), Hyperbilirubinemia
(Obata, 1983), Phospholipidosis (Hirode et al., 2008)
(0.07–0.42)# Cholestasis (Regal et al., 1987), Hyperbilirubinemia
(Waitzkin, 1962), Phospholipidosis (Halliwell, 1997)
Neutral Lipids
"
Phospholipids
"
10
ATP ;
LDH " 5 10
Troglitazone (TGZ)
(5, 10, 25)
Mrp2
inhibition ;
5 10 10 25 (2.04–6.39) (Loi et al., 1999) Cholestasis (Funk et al., 2001a) (2.04–6.32)# Cholestasis (Menon et al., 2001)
Neutral Lipids
"
Phospholipids
"
ATP ;
LDH "
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Metformin (MET)
(10, 25, 50)
Mrp2
inhibition ;
(15.81–83.92) (Choi et al., 2010;
Lal and Jain, 2010)
(6.04–18.72)#
Neutral Lipids
"
Phospholipids
"
ATP ;
LDH " 50
Fenoﬁbrate (FFB) (5,
10, 25)
Mrp2
inhibition ;
(2.27–9.83) (Li et al., 2009) (21.33–31.59)#
Neutral Lipids
"
Phospholipids
"
ATP ;
LDH " 25 25
Ibuprofen (IBU) (10,
20, 50)
Mrp2
inhibition ;
(25.74–129.91) (Khan and
Akhter, 2005; Newa et al., 2008)
(269.5–
322.85)#
Neutral Lipids
"
Phospholipids
"
ATP ;
LDH " 50 50
Acetaminophen
(ACT) (250, 500,
1000)
Mrp2
inhibition ;
(80.31–365.81) (Yamamoto et al.,
2007; Yamasaki et al., 2011)
ALT/AST increase, hepatocellular damage (Gardner
et al., 1998)
(132.3)# ALT/AST increase, Hepatocellular damage (Bolesta and
Haber, 2002)
Neutral Lipids
"
Phospholipids
"
ATP ;
LDH "
Valproic Acid (VPA)
(10, 20, 50)
Mrp2
inhibition ;
(566.82–1292.86) (Blotnik et al.,
1996; Ohshiro et al., 2003)
Mitochondrial impairment (Tong et al., 2005), Steatosis
(Lewis et al., 1982)
(180.29–
291.24)#
Mitochondrial impairment (Finsterer and Zarrouk,
2012), Steatosis (Zimmerman and Ishak, 1982)
Neutral Lipids
"
Phospholipids
"
ATP ;
LDH "
# Human Cmax values were extrapolated from Goodman & Gilman’s. The pharmacological basis of therapeutics, 12e.
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Fig. 1. Morphological differences of rat hepatocytes in presence or absence of second layer of Matrigel™. Representative phase contrast images of rat hepatocytes cultured
with single (A–E) or double addition of Matrigel™ top layer (F–J) at selected timepoints. Bar = 50 lm.
84 D. Germano et al. / Toxicology in Vitro 30 (2015) 79–94of scanned images conﬁrmed that the average intensity and the
average area of ﬂuorescent signal were signiﬁcantly higher in
hepatocytes cultured with 4 layers of Matrigel™ (Fig. 2D and E).
In addition, the number of viable cells was higher with increasing
number of the layers of Matrigel™ applied (Fig. 2C). Based on these
ﬁndings, all hepatocyte experiments were performed in cultures
with 4 layers of Matrigel™.
The analysis of supernatants collected at different timepoints
displayed the maintenance of speciﬁc functions such as albumin
secretion (Fig. 3A) and urea synthesis (Fig. 3B) over 14 days of cul-
ture. Moreover, the expression of speciﬁc genes at several0
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accumulation in canaliculi of rat hepatocytes cultured in presence of two (F), three (G
Bar = 50 lm. Error bars represent standard deviation (n = 3).timepoints (day 1, 3, 7, 10, and 14) was assessed by RT–PCR. As
shown in Fig. 3C, the expression of hepatocyte speciﬁc genes such
as canalicular and sinusoidal transporters was stable and main-
tained over the whole period of culture, as well as the expression
of nuclear receptor and CYPs.
3.2. Evaluation of drug-induced effects after 14 days repeated
treatments
The chronic-like toxicity of 10 selected compounds was investi-
gated by daily repetitive treatment for 14 days. The concentrations3rd
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D. Germano et al. / Toxicology in Vitro 30 (2015) 79–94 85selected for the 14-day long-term treatments derived from 48-h
cytotoxicity studies. Three non-cytotoxic concentrations for 48-h
incubation were chosen (low, middle, high) for each compound.
The highest non-cytotoxic concentration during 48 h, as measured
by cellular viability (ATP) and cellular leakage (LDH), was selected
as the high dose for the 14-day treatments (Suppl. Fig. 2). Non-
cytotoxic concentrations were chosen in order to observe and
identify speciﬁc responses in absence of overt cell death due to
unspeciﬁc mechanisms. Table 2 illustrates the list of compounds
and concentrations used for the long-term treatments. HCI was
used to measure endpoints associated with liver pathological or
mechanism-based features. Inhibition of Mrp2-mediated canalicu-
lar transport, intracellular accumulation of neutral lipids in the
cytoplasm (steatosis) and accumulation of phospholipids in organ-
elles of lysosomal origin were evaluated with speciﬁc ﬂuorescent
dyes. Cell number, also monitored over 14 days of treatment, was
not affected by any of the compounds (data not shown). On day
1, none of the selected compounds did induce signiﬁcant changes
in any of the investigated endpoints and thus were not included
in the following illustration of results.
CsA was daily administered at concentrations of 0.3, 1 and 3 lM
for 14 days. On day 1, 3, 7, 10 and 14, samples were investigated for
the selected endpoints. Morphological investigations revealed that
the 3 lM CsA exposure resulted into accumulation of vacuoles
within the cytoplasm associated with minimal loss of hepatic mor-
phology on day 3 (Fig. 4D). An increased number of vacuoles and
disruption of canalicular network was observed after 14 days
(Fig. 4P). The presence of vacuoles was visible already at the lower
concentrations from day 7 (Fig. 4G, J, N, O).
Further biochemical investigations are shown in Fig. 5A. The
intracellular ATP levels were not affected within the ﬁrst days of
culture, but decreased only after 14 days of treatment with CsA
at the concentrations of 1 lM (p < 0.05) and 3 lM (p < 0.01)
Accordingly, LDH levels increased at day 14 at both 1 lMA B
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whole period of culture (C). Error bars represent standard deviation (n = 3).(p < 0.05) and 3 lM CsA concentrations (p < 0.01). In contrast,
CsA affected the Mrp2-mediated canalicular transport already after
3 days of exposure at 3 lM (p < 0.0001). The inhibition occurred
in a time- and concentration-fashion and resulted in a 54% spot
average intensity decrease at 0.3 lM (p < 0.0001) and 76%
decrease at 1 lM CsA on day 14. Images conﬁrmed that partial
inhibition of Mrp2-mediated canalicular transport occurred
already after 3 days at 3 lMdose (Suppl. Fig. 3D). This resulted into
a reduced quantiﬁcation of ﬂuorescent signal, as displayed by the
cyan spots overlaying with the DCF (Suppl. Fig. 3H). As a conse-
quence of the reduced export of DCF, a clear retention of the dye
within the cytoplasm was observed; such effect was exacerbated
after 14 days of treatment (Suppl. Fig. 3N–P). The effect of CsA on
lipid metabolism was evaluated by reagents staining respectively
neutral lipids and phospholipids. As shown in Fig. 5A, the accumu-
lation of neutral lipids was detected already after 3 days of treat-
ment (3 lM, p < 0.01). The size of intracellular vacuoles
increased over the time of treatment (Suppl. Fig. 4). On contrast,
CsA exposure did not affect the amount of phospholipids.
Exposure to AMD did not affect intracellular ATP levels, but
affected LDH levels at late stages of treatment (day 10 and 14) at
the highest drug concentration only (5 lM, p < 0.05) (Fig. 5B).
AMD treatment was associated with increase of phospholipids
content already after 3 days at a concentration of 5 lM
(p < 0.05), resulting in signiﬁcant changes after 14 days at concen-
trations of 2.5 lM (p < 0.05) as well as a at 5 lM (p < 0.001)
(Images taken at day 3 and 14 (Suppl. Fig. 5) displayed the increase
of phospholipids in hepatocytes treated with AMD. Increased ﬂuo-
rescence signal reﬂecting the accumulation of phospholipids was
observed at 5 lM concentrations (Fig. Suppl. Fig. 5L and P), as com-
pared to vehicle control (Suppl. Fig. 5I and M).
LDH release following CPZ exposure was found only at day 14 of
treatment (5 lM, p < 0.01; 10 lM, p < 0.05) (Fig. 6B), whereas
Mrp2-mediated canalicular transport was reduced at day 3 at all0
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In addition, 10 lM CPZ enhanced the content of intracellular
phospholipids after 7 and 14 days (p < 0.05).
Similarly, treatment of rat hepatocytes with TGZ resulted into
inhibition of canalicular transport after 3 days at all concentrations
(5 lM, p < 0.05; 10 lM, p < 0.001; 25 lM, p < 0.001) (Fig. 7A),
whereas no cytotoxicity was observed over 14-day exposure.
Exposure of RGZ resulted into accumulation of neutral lipids by
day 14 at the highest concentration (50 lM, p < 0.05) (Fig. 6A;
Suppl. Fig. 6K, L, Q and P) which was associated at the same time
with increased leakage of LDH.
Cells treated with ACT and VPA did not display any sign of cyto-
toxicity (Fig. 9A and B). In addition canalicular transport and lipid
metabolism were not affected. MET 50 lM (Fig. 7B), FFB 25 lM
(Fig. 8A) and IBU 50 lM (Fig. 8B) treatments were only associated
with LDH release at day 10 and 14.4. Discussion
The data presented here illustrate further improvement of the
rat hepatocyte Collagen I-Matrigel™ sandwich in vitro model,
where primary rat hepatocytes were maintained in a functional
state for a period of 14 days. The addition of multiple layers of
Matrigel™ has been demonstrated to be a robust method for the
maintenance of hepatocyte morphology and speciﬁc functions.
Mrp2-mediated transport quantiﬁed by HCI was enhanced when
hepatocytes received 4 layers of Matrigel™ over 2 weeks of cul-
ture. In these conditions, the expression of liver speciﬁc genes,
such as transporters, nuclear receptor and CYPs was stable over
the whole culture duration. However, in this setting the addition
of a low percentage of serum as well as the presence of EGF in
the cell culture medium did not improve the cells status, despite
some published evidences showing enhancement of long-termmaintenance and survival of rat hepatocytes (Farkas and
Tannenbaum, 2005). (Suppl. Fig. 1B and F).
These culture conditions allowed mimicking chronic treatment
by multiple exposures of hepatocytes to different hepatotoxicants.
By combining a stable and reproducible in vitro culture system
exposed daily to low non-cytotoxic concentrations for 14 days
together with HCI technology, speciﬁc cellular responses associ-
ated with liver pathological features could be monitored and
quantiﬁed.
In some instances, drug withdrawals from market were the
result of ‘‘Hy’s law’’ cases, indicated by a 2-fold bilirubin increase
with a concomitant occurrence of 3-fold ALT increase in plasma.
These combined events are admitted as a high risk of fatal liver
failure. After being formed in the systemic circulation, bilirubin
is transported into the hepatocytes, metabolized to give digluc-
uronide metabolite and excreted into the bile by Mrp2. Mrp2
(ABCC2) is also known to mediate the biliary excretion of gluta-
thione and sulfate metabolites. Mrp2 impairment can affect the
hepatic clearance of endogenous compounds, such as steroids,
leukotrienes and many clinically important drugs (Gerk and
Vore, 2002). The clinical importance of Mrp2-inhibition has been
demonstrated by Mrp2 gene mutations (Kartenbeck et al., 1996)
as well as by the down-regulation of its expression (Terui et al.,
2011; Yamada et al., 2005) and its association with the occur-
rence of hyperbilirubinemia. Hence, it is of importance to dispose
of an assay to avoid drug inhibition of Mrp2. The present data
show that the exposure of rat hepatocytes to CsA, CPZ and TGZ
resulted into the inhibition of Mrp2-mediated transport of DCF
in a dose- and time-dependent manner. A reduction of ﬂuorescent
signal in the canaliculi followed by accumulation of the ﬂuores-
cent dye into the cytoplasm was the result of Mrp2 inhibition.
These effects were shown to occur already after 3 days of treat-
ment, whereas cytotoxicity was observed only after 10 days of
exposure. Side effects of the immunosuppressive drug CsA are
Fig. 5. Graphs showing the effects of CsA (A) and AMD (B) on inhibition of Mrp2-mediated canalicular transport, accumulation of neutral lipids and phospholipids,
intracellular ATP and LDH release. Error bars represent standard error (⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001, ⁄⁄⁄⁄p < 0.0001; two-way ANOVA).
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animals and man (Kahan, 1989; Wiesner et al., 1990). The most
common abnormalities related to hepatotoxicity are increases ofserum bile salt levels, cholestasis (Kahan, 1989; Myara et al.,
1996) and hyperbilirubinemia (Ertorer et al., 1997). Mrp2,
together with BSEP and MDR1, are ATP-dependent transporters
Fig. 6. Graphs showing the effects of RGZ (A) and CPZ (B) on inhibition of Mrp2-mediated canalicular transport, accumulation of neutral lipids and phospholipids,
intracellular ATP and LDH release. Error bars represent standard error (⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001, ⁄⁄⁄⁄p < 0.0001; two-way ANOVA).
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Kobayashi et al., 2004). TGZ has been shown to decrease Mrp2
expression in liver (Foster et al., 2012), whereas CPZ has beenshown to inhibit directly Mrp2-mediated transport of estradiol-
17-b-glucuronide (Pedersen et al., 2008). Other studies suggested
that an imbalance of intracellular ATP might occur following CsA,
Fig. 7. Graphs showing the effects of TGZ (A) and MET (B) on inhibition of Mrp2-mediated canalicular transport, accumulation of neutral lipids and phospholipids,
intracellular ATP and LDH release. Error bars represent standard error (⁄p < 0.05, ⁄⁄⁄p < 0.001; two-way ANOVA).
D. Germano et al. / Toxicology in Vitro 30 (2015) 79–94 89CPZ and TGZ treatment, leading to a reduction of ATP-dependent
canalicular transport of bile salts in the liver (Ballantyne et al.,
1989; Funk et al., 2001; Samuels and Carey, 1978; Ziegler andFrimmer, 1986). However, changes in the content of ATP during
early stages were not observed here, suggesting that additional
mechanisms must be involved.
Fig. 8. Graphs showing the effects of FFB (A) and IBU (B) on inhibition of Mrp2-mediated canalicular transport, accumulation of neutral lipids and phospholipids, intracellular
ATP and LDH release. Error bars represent standard error (⁄p < 0.05, ⁄⁄p < 0.01; two-way ANOVA).
90 D. Germano et al. / Toxicology in Vitro 30 (2015) 79–94AMD is an antiarrhythmic drug being reported, among several
other cationic amphiphilic drugs such as CPZ, to induce PLD
(Halliwell, 1997). Both drugs are regarded as inhibitors of phos-
pholipase activity and therefore impairing phospholipid catabo-lism (Shaikh et al., 1987). While PLD does not constitute overt
toxicity per se, it has been reported to be associated with drug or
metabolite accumulation in affected tissues (Hruban, 1984), and
as such, possibly contributing to untoward side effects. In addition,
Fig. 9. Graphs showing the effects of ACT (A) and VPA (B) on inhibition of Mrp2-mediated canalicular transport, accumulation of neutral lipids and phospholipids,
intracellular ATP and LDH release. Error bars represent standard error.
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associated with PLD has been reported (Oikawa et al., 2005). The
treatment of rat hepatocytes with AMD and CPZ at low concentra-tions did not cause cytotoxicity. Increase of LDH was observed in
the supernatant of hepatocytes treated only with higher concen-
trations at day 14 of culture (AMD 5 lM, CPZ 5 and 10 lM). On
92 D. Germano et al. / Toxicology in Vitro 30 (2015) 79–94the other hand, the HCI investigations revealed a strong accumula-
tion of phospholipids already after few days and increased over
time in a concentration-dependent fashion. These observations
were in line with several studies reporting occurrence of PLD
in vivo (Hirode et al., 2008; Lewis et al., 1990) and in vitro
(Fujimura et al., 2007; Kuroda and Saito, 2010; Morelli et al.,
2006; Schurdak et al., 2007) detected with cell-based ﬂuorescence
assays.
The investigation of steatosis displayed false negative and false
positive results: the data generated in vitro were not correlating
with in vivo ﬁndings. CsA, which has never been reported to induce
steatosis in vivo in rats or in human, produced a signiﬁcant
accumulation of fatty microvesicles in rat hepatocytes in vitro.
Hence, this steatotic-like in vitro effect of CsA can be considered
as an artifact, which has no in vivo relevance. RGZ has been shown
to be cytotoxic in vitro to hepatocytes from different donors
(EC(50) < 100 lM) (Lloyd et al., 2002). In the present study RGZ
was signiﬁcantly cytotoxic at 50 lM concentration and above. Sev-
eral studies illustrated a reduction in hepatic steatosis by RGZ in
human type 2 diabetic patients (Carey et al., 2002; Mayerson
et al., 2002). Here an accumulation of lipid droplets was detected,
even though the effect was observed only at late stages of
treatment and was associated with cytotoxic effect. These results
suggest that the lipid metabolism may be affected following RGZ
treatment in vitro, but it cannot be excluded that impairment of
lipid metabolism represents a secondary effect due to cytotoxicity.
The mechanisms leading to hepatocellular injury caused by RGZ
are not very well understood. It is possible that the chronic expo-
sure to RGZ, as shown in other studies (Feinstein et al., 2005), could
directly interfere with mitochondrial functions, resulting in
impairment of mitochondrial b-oxidation of fatty acids leading to
steatosis. Likewise, VPA is known to induce cases of steatosis in
patients and in some animal models through the inhibition of b-
oxidation and the synthesis of fatty acids (Fromenty and
Pessayre, 1995; Lee et al., 2007). Abnormal lipid metabolism was
observed after acute high dose exposure in vivo (Lee et al., 2007)
and in vitro using HCI approach (Fujimura et al., 2009). In this study
conditions, accumulation of lipid following 14 days exposure was
not observed. Given the fact that the selected dose range (25–
100 lM) was much lower than acute 24-h studies (1–3 mM) (Lee
et al., 2008) and Cmax values found in rat plasma (Blotnik et al.,
1996; Ohshiro et al., 2003), it may be speculated that higher
concentrations might have been necessary to elicit a steatogenic
response. Further incubation of rat hepatocytes with higher
concentration of VPA (500–3000 lM) for 72 h resulted into
dose-dependent accumulation of neutral lipids (Suppl. Fig. 7).
MET, FFB, IBU and ACT, have not been reported to cause hyper-
bilirubinemia, steatosis or phospholipidosis after in vivo treatment
(Table 2), thus served as negative controls for the three speciﬁc HCI
readouts investigated in our long-term in vitro system. Addition-
ally, each of the other selected compounds is a known hepatotox-
icant for one speciﬁc pathological feature, either for
hyperbilirubinemia or steatosis or phospholipidosis. Hence, each
compound served as a negative control for the two other studied
untoward events, e.g., AMD was considered a positive control for
phospholipidosis, but a negative one for hyperbilirubinemia and
steatosis. Short-term acute high-concentration in vitro toxicity
testing of hepatocytes normally turned out to have little predictiv-
ity of the hepatotoxicity observed in vivo, either in animals or in
man (McKim, 2010; Xu et al., 2004). Since the occurrence of hepa-
totoxicity is a complex process, the use of a panel of tests covering
different types of liver injury has been suggested (Guguen-
Guillouzo and Guillouzo, 2010). By selecting multiple parameters
associated with speciﬁc in vivo hepatotoxic functions and
endpoints, this work represents a more germane approach.
Multi-parametric cellular imaging-based approaches have alreadybeen used to investigate DILI (Donato et al., 2012; van de Water
et al., 2011; Xu et al., 2004, 2008). In these studies, cells have been
exposed to compounds up to a maximum of 72 h. In many cases,
cell lines without drug metabolizing activity or liver-speciﬁc func-
tions were used. For these reasons, they may be regarded as
descriptors of acute general organ toxicity rather than speciﬁc hep-
atotoxicity. In general the high concentrations used are signiﬁ-
cantly exceeding the exposure detected in animals or man,
inducing unspeciﬁc cytotoxicity confounding interpretations of
more liver-speciﬁc event. In fact, hepatocytes treated with AMD
for 48 h displayed dose-dependent accumulation of phospholipids,
but the treatment with high concentrations (10–30 lM) was
associated with cytotoxicity (Suppl. Fig. 2). For that purpose sub-
cytotoxic concentrations were always used, which limited the
occurrence of unspeciﬁc effects. Table 2 shows that the concentra-
tions used for the 2-week hepatocyte treatments were comparable
to Cmax achieved in animal studies and were in the therapeutic
exposure range found in patients. In addition, Table 2 summarizes
the results obtained under these experimental conditions com-
pared to preclinical and clinical ﬁndings. In order to have a more
precise in vitro–in vivo extrapolation, the use of toxicokinetics data
as well as physiologically based toxicokinetics modeling (PBTK) is
recommended (Coecke et al., 2013). The nominal concentrations
applied to the culture systems may deviate from the actual concen-
tration of the compound due to the occurrence of multiple possible
events, such as accumulation, evaporation, binding to plastic and/
or medium components, uptake and metabolism (Blaauboer, 2010;
Tanneberger et al., 2010). The combination of toxicodynamic and
toxicokinetic approaches has been extensively investigated in the
EU funded 7th Framework Project Predict-IV. Results obtained sup-
port the usefulness of in vitro biokinetic data in the interpretation
of in vitro repeated exposure toxicity data (Broeders et al., 2013;
Coecke et al., 2013; Parmentier et al., 2013). Overall, despite the
limited number of molecules tested, this approach displayed some
sensitivity (able to detect true positives) and speciﬁcity (able to
detect true negatives) for the prediction of PLD and inhibition of
Mrp2-mediated transport. Indeed, on one hand, the treatment of
hepatocytes with PLD-inducing compounds (AMD and CPZ) and
hyperbilirubinemia/cholestasis-inducing compounds (CsA, TGZ,
CPZ) effectively resulted in the expected effects. On the other hand,
the predictive value (sensitivity + speciﬁcity) for steatosis
remained unsatisfactory as the occurrence of false negative and
false positive outcome was observed upon treatment with VPA
and CsA respectively.
In summary, these results provided evidence that cellular
responses to hepatotoxicants can be monitored using high content
microscopy. Primary rat hepatocytes cultured in Collagen I/Matri-
gel™ sandwich conﬁguration have been evaluated and shown to
be a suitable system for the investigation of some chronic-like
drug-induced toxicity, given the capability to obtain full polariza-
tion. By using subtoxic concentrations, this model can indeed
mimic the repeated exposure of cells to hepatotoxicants and could
be used to improve the prediction of some hepatotoxicity in pre-
clinical development. The analysis aimed at ﬁnding parameters
that predict toxicity-related events before actual cell death
occurred. The data obtained suggested that liver speciﬁc functional
impairments investigated with cellular imaging technology were
enhanced over time and occurred before cytotoxicity.
The limited compound set used in this study allowed the in vitro
monitoring of PLD induction and Mrp2 inhibition, known to occur
in both preclinical species and human. However, a similar
approach using human primary hepatocytes could be used to
assess more human-speciﬁc drug related events. The present work
provides an improved in vitro chronic-like approach for the safety
proﬁling of future compounds, in order to avoid hepatotoxic
molecules.
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